vs
GLOBUS MEDICAL INC（GMED）与Penumbra Inc（PEN）财务数据对比。点击上方公司名可切换其他公司
GLOBUS MEDICAL INC的季度营收约是Penumbra Inc的2.1倍（$826.4M vs $385.4M）。GLOBUS MEDICAL INC净利率更高（17.0% vs 12.3%，领先4.7%）。GLOBUS MEDICAL INC同比增速更快（25.7% vs 22.1%）。GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $68.0M）。过去两年Penumbra Inc的营收复合增速更高（17.6% vs 16.7%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
Penumbra Inc是2004年由Arani Bose与Adam Elsesser联合创立的美国医疗器械企业，总部位于加利福尼亚州阿拉米达，核心业务为研发、生产中风、动脉瘤等血管疾病介入治疗所用的专业医疗设备，产品已在全球多个国家的临床诊疗场景中投入使用。
GMED vs PEN — 直观对比
营收规模更大
GMED
是对方的2.1倍
$385.4M
营收增速更快
GMED
高出3.6%
22.1%
净利率更高
GMED
高出4.7%
12.3%
自由现金流更多
GMED
多$134.3M
$68.0M
两年增速更快
PEN
近两年复合增速
16.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $385.4M |
| 净利润 | $140.6M | $47.3M |
| 毛利率 | 68.4% | 68.0% |
| 营业利润率 | 20.5% | 15.4% |
| 净利率 | 17.0% | 12.3% |
| 营收同比 | 25.7% | 22.1% |
| 净利润同比 | 430.4% | 40.6% |
| 每股收益（稀释后） | $1.01 | $1.20 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDPEN
| Q4 25 | $826.4M | $385.4M | ||
| Q3 25 | $769.0M | $354.7M | ||
| Q2 25 | $745.3M | $339.5M | ||
| Q1 25 | $598.1M | $324.1M | ||
| Q4 24 | $657.3M | $315.5M | ||
| Q3 24 | $625.7M | $301.0M | ||
| Q2 24 | $629.7M | $299.4M | ||
| Q1 24 | $606.7M | $278.7M |
净利润GMEDPEN
| Q4 25 | $140.6M | $47.3M | ||
| Q3 25 | $119.0M | $45.9M | ||
| Q2 25 | $202.8M | $45.3M | ||
| Q1 25 | $75.5M | $39.2M | ||
| Q4 24 | $26.5M | $33.7M | ||
| Q3 24 | $51.8M | $29.5M | ||
| Q2 24 | $31.8M | $-60.2M | ||
| Q1 24 | $-7.1M | $11.0M |
毛利率GMEDPEN
| Q4 25 | 68.4% | 68.0% | ||
| Q3 25 | 67.2% | 67.8% | ||
| Q2 25 | 66.6% | 66.0% | ||
| Q1 25 | 67.3% | 66.6% | ||
| Q4 24 | 59.9% | 66.8% | ||
| Q3 24 | 56.8% | 66.5% | ||
| Q2 24 | 58.7% | 54.4% | ||
| Q1 24 | 60.2% | 65.0% |
营业利润率GMEDPEN
| Q4 25 | 20.5% | 15.4% | ||
| Q3 25 | 17.9% | 13.8% | ||
| Q2 25 | 10.2% | 12.0% | ||
| Q1 25 | 16.2% | 12.4% | ||
| Q4 24 | 9.2% | 13.6% | ||
| Q3 24 | 7.7% | 11.7% | ||
| Q2 24 | 7.9% | -27.0% | ||
| Q1 24 | 1.3% | 4.3% |
净利率GMEDPEN
| Q4 25 | 17.0% | 12.3% | ||
| Q3 25 | 15.5% | 12.9% | ||
| Q2 25 | 27.2% | 13.3% | ||
| Q1 25 | 12.6% | 12.1% | ||
| Q4 24 | 4.0% | 10.7% | ||
| Q3 24 | 8.3% | 9.8% | ||
| Q2 24 | 5.0% | -20.1% | ||
| Q1 24 | -1.2% | 3.9% |
每股收益（稀释后）GMEDPEN
| Q4 25 | $1.01 | $1.20 | ||
| Q3 25 | $0.88 | $1.17 | ||
| Q2 25 | $1.49 | $1.15 | ||
| Q1 25 | $0.54 | $1.00 | ||
| Q4 24 | $0.19 | $0.88 | ||
| Q3 24 | $0.38 | $0.75 | ||
| Q2 24 | $0.23 | $-1.55 | ||
| Q1 24 | $-0.05 | $0.28 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $186.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.6B | $1.4B |
| 总资产 | $5.3B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMEDPEN
| Q4 25 | $557.2M | $186.9M | ||
| Q3 25 | $18.8M | $321.0M | ||
| Q2 25 | — | $421.8M | ||
| Q1 25 | — | $376.1M | ||
| Q4 24 | $890.1M | $324.4M | ||
| Q3 24 | $71.9M | $280.5M | ||
| Q2 24 | $82.5M | $288.3M | ||
| Q1 24 | $80.4M | $223.1M |
股东权益GMEDPEN
| Q4 25 | $4.6B | $1.4B | ||
| Q3 25 | $4.4B | $1.4B | ||
| Q2 25 | $4.3B | $1.3B | ||
| Q1 25 | $4.1B | $1.2B | ||
| Q4 24 | $4.2B | $1.2B | ||
| Q3 24 | $4.1B | $1.1B | ||
| Q2 24 | $4.0B | $1.2B | ||
| Q1 24 | $3.9B | $1.2B |
总资产GMEDPEN
| Q4 25 | $5.3B | $1.8B | ||
| Q3 25 | $5.1B | $1.7B | ||
| Q2 25 | $5.0B | $1.7B | ||
| Q1 25 | $4.7B | $1.6B | ||
| Q4 24 | $5.3B | $1.5B | ||
| Q3 24 | $5.1B | $1.5B | ||
| Q2 24 | $5.0B | $1.5B | ||
| Q1 24 | $4.9B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $86.5M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | $68.0M |
| 自由现金流率自由现金流/营收 | 24.5% | 17.7% |
| 资本支出强度资本支出/营收 | 5.6% | 4.8% |
| 现金转化率经营现金流/净利润 | 1.77× | 1.83× |
| 过去12个月自由现金流最近4个季度 | $588.8M | $174.9M |
8季度趋势，按日历期对齐
经营现金流GMEDPEN
| Q4 25 | $248.6M | $86.5M | ||
| Q3 25 | $249.7M | $58.3M | ||
| Q2 25 | $77.9M | $44.9M | ||
| Q1 25 | $177.3M | $49.0M | ||
| Q4 24 | $210.3M | $51.1M | ||
| Q3 24 | $203.7M | $56.5M | ||
| Q2 24 | $54.3M | $22.6M | ||
| Q1 24 | $52.4M | $38.3M |
自由现金流GMEDPEN
| Q4 25 | $202.4M | $68.0M | ||
| Q3 25 | $213.9M | $42.0M | ||
| Q2 25 | $31.3M | $29.4M | ||
| Q1 25 | $141.2M | $35.5M | ||
| Q4 24 | $193.2M | $45.7M | ||
| Q3 24 | $161.7M | $51.0M | ||
| Q2 24 | $26.5M | $18.1M | ||
| Q1 24 | $23.8M | $32.5M |
自由现金流率GMEDPEN
| Q4 25 | 24.5% | 17.7% | ||
| Q3 25 | 27.8% | 11.8% | ||
| Q2 25 | 4.2% | 8.7% | ||
| Q1 25 | 23.6% | 11.0% | ||
| Q4 24 | 29.4% | 14.5% | ||
| Q3 24 | 25.8% | 16.9% | ||
| Q2 24 | 4.2% | 6.0% | ||
| Q1 24 | 3.9% | 11.7% |
资本支出强度GMEDPEN
| Q4 25 | 5.6% | 4.8% | ||
| Q3 25 | 4.7% | 4.6% | ||
| Q2 25 | 6.2% | 4.6% | ||
| Q1 25 | 6.0% | 4.2% | ||
| Q4 24 | 2.6% | 1.7% | ||
| Q3 24 | 6.7% | 1.8% | ||
| Q2 24 | 4.4% | 1.5% | ||
| Q1 24 | 4.7% | 2.1% |
现金转化率GMEDPEN
| Q4 25 | 1.77× | 1.83× | ||
| Q3 25 | 2.10× | 1.27× | ||
| Q2 25 | 0.38× | 0.99× | ||
| Q1 25 | 2.35× | 1.25× | ||
| Q4 24 | 7.94× | 1.52× | ||
| Q3 24 | 3.93× | 1.91× | ||
| Q2 24 | 1.71× | — | ||
| Q1 24 | — | 3.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
PEN
暂无分部数据
